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Background: Malignant cells in tumours of B-cell origin account for 0.1% to 98% of the total cell content,
depending on disease entity. Recently, gene expression profiles (GEPs) of B-cell lymphomas based on microarray
technologies have contributed significantly to improved sub-classification and diagnostics. However, the varying
degrees of malignant B-cell frequencies in analysed samples influence the interpretation of the GEPs. Based on
emerging next-generation sequencing technologies (NGS) like tag sequencing (tag-seq) for GEP, it is expected that
the detection of mRNA transcripts from malignant B-cells can be supplemented. This study provides a quantitative
assessment and comparison of the ability of microarrays and tag-seq to detect mRNA transcripts from malignant B-
cells. A model system was established by eight serial dilutions of the malignant B-cell lymphoma cell line, OCI-Ly8,
into the embryonic kidney cell line, HEK293, prior to parallel analysis by exon microarrays and tag-seq.
Results: We identified 123 and 117 differentially expressed genes between pure OCI-Ly8 and HEK293 cells by exon
microarray and tag-seq, respectively. There were thirty genes in common, and of those, most were B-cell specific.
Hierarchical clustering from all dilutions based on the differentially expressed genes showed that neither
technology could distinguish between samples with less than 1% malignant B-cells from non-B-cells. A novel
statistical concept was developed to assess the ability to detect single genes for both technologies, and used to
demonstrate an inverse proportional relationship with the sample purity. Of the 30 common genes, the detection
capability of a representative set of three B-cell specific genes - CD74, HLA-DRA, and BCL6 - was analysed. It was
noticed that at least 5%, 13% and 22% sample purity respectively was required for detection of the three genes by
exon microarray whereas at least 2%, 4% and 51% percent sample purity of malignant B-cells were required for
tag-seq detection.
Conclusion: A sample purity-dependent loss of the ability to detect genes for both technologies was
demonstrated. Taq-seq, in comparison to exon microarray, required slightly less malignant B-cells in the samples
analysed in order to detect the two most abundantly expressed of the selected genes. The results show that
malignant cell frequency is an important variable, with fundamental impact when interpreting GEPs from both
technologies.
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Malignant cells in tumour tissues of B-cell origin ac-
count for 0.1% to 98% of the total cell content depend-
ing on the specific disease entity [1,2]. Varying content
in the B-cell tumours of normal leucocytes, lymphocytes
and stromal cells with their own individual GEPs poses a
challenge for identification of specific malignant B-cell
signatures [3]. Although several studies have successfully
identified gene expression patterns of tumour samples,
their interpretation is often confounded by a lack of in-
formation about the varying presence of normal cells
within the tumour biopsies. In recent years, microarray
technology has been the default technology for detection
of global GEP in different cancer types [4]. However, it is
difficult to quantify expression of low-abundant mRNA
transcripts by microarrays, since low hybridisation inten-
sity signals are difficult to distinguish from background
levels arising from non-specific hybridisation. Due to an
absence of background signals, NGS technologies, in-
cluding tag-seq, have the potential to out-perform or at
least supplement the exon microarray [5,6]. However,
there is a need to explore the technical limits of the
exon microarray and tag-seq for identification and inter-
pretation of mRNA transcript profiles, in particular ma-
lignant B-cells in a pool of non-malignant cells.
The Affymetrix GeneChip Human Exon 1.0 ST Array
is a dense microarray designed for GEP, featuring 6.5
million probes corresponding to known targets and pre-
dicted exons spanning the entire human genome [7].
The probes interrogate different regions of the same
mRNA transcript showing variation in probe-target hy-
bridisation intensities across the transcript. This vari-
ation is sequence-dependent and affected by probe-
target binding strength. The probe-target binding
strength is affected by competing formation of probe-
probe dimers and secondary structures in probes, result-
ing in background noise from which low hybridisation
intensity signals can be difficult to distinguish [5,8].
Gene expression levels are measured as probe-target hy-
bridisation intensities, and all values are background cor-
rected, with the inter-array quantile normalised to
remove systematic biases, providing relative rather than
absolute gene expression levels [9]. The next-generation
sequencing-based tag-seq technology uses two restric-
tion enzymes, NlaIII and MmeI, to generate cDNA tags
that are reverse transcribed from mRNA transcripts, byTable 1 Library and annotation results for tag-seq data
Purity 100% 30% 20% 10%
Lib. size 543,848 679,415 756,581 2,759,286
Annotated 477,707 580,388 677,669 2,429,976
Percent 87.8 85.4 89.6 88.1cutting from the 3´-end CATG to the poly(A)-tail and
17–19 bp downstream of the first restriction enzyme site
[6,10,11]. Clonal copies of each cDNA tag are generated
on a solid surface flow cell using a bridge amplification
approach without any predefined array attached probes
before sequencing. During sequencing, the numerical
frequencies of each tag are recorded and provide abso-
lute gene expression values [6].
The present study is based on a model system,
where malignant B-cells were serially diluted into em-
bryonic kidney cells at eight different cellular frequen-
cies illustrating varying levels of malignant B-cell
sample purities. Total RNA from each of the cell
populations was tested in parallel to generate data,
both by exon microarrays using the Affymetrix Gene-
Chip Human Exon 1.0 ST platform and tag-seq using
the Illumina Genome Analyzer platform, as well as
RT-qPCR validation of three selected genes. The goal
for this work was to develop a quantification method
that could be used for assessing and comparing the
ability to detect malignant B-cell transcripts based on
exon microarray and tag-seq as a function of sample
purity.
Results
Detection ability of exon microarray and tag-seq
To compare the detection abilities, serial dilutions of
eight samples of mixed cell populations from the human
malignant B-cell line, OCI-Ly8, into the human embry-
onic kidney cell line, HEK293, at the cellular frequencies
0%, 0.5%, 1%, 5%, 10%, 20%, 30%, and 100% malignant
B-cells, were prepared by fluorescent activated cell sort-
ing (FACS). This dilution scheme was chosen to demon-
strate resolution detection for small amounts of
malignant B-cells. Total RNA from all samples was pre-
pared and analysed using the two technologies in ques-
tion. Overall, mRNA expression levels of 17,816 RefSeq
transcripts and full-length mRNA transcripts using the
core probes of the exon microarray were determined,
and the number of unique genes detected above back-
ground (DABG) was 11,112. In parallel, exactly the same
total RNA from all samples was used to prepare small
tags of 17 bp cDNA sequences, which yielded 0.5-2.8
million reads per sample (Table 1). In two of the samples,
a high number of reads was noticed. This was probably
the consequence of a repetition of the pre-processing for5% 1% 0.50% 0% Unique
805,851 520,166 450,074 2,432,248 134,579
713,144 459,150 391,854 2,120,204 82,748
88.5 88.3 87.1 87.2 61.5
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dards in the first pre-processing. The sub-sampling, how-
ever, successfully remedied this problem. Of each sample,
85.4-89.6% of the reads were mapped to the ENSEMBL
Homo Sapiens cDNA reference transcriptome (release
63), allowing 1 mismatch per read. Summarising reads
from all samples, 134,579 unique reads were identified
and 61.5% of these were annotated, while 38.5% did not
match any known human mRNA transcript sequence.
The unique reads from all eight samples were summarised
to gene levels, resulting in the detection of expression of a
total of 12,441 unique genes. The average number of tags
per gene was 5.8, while 9,784 genes were both DABG by
the exon microarray and identified by tag-seq. The entire
data generation and analysis flow is illustrated in
Additional file 1.
Differentially expressed genes by exon microarray and
tag-seq
Differentially expressed genes were determined between
the pure OCI-Ly8 and HEK293 cell line samples using a
false discovery rate (FDR) of less than 5%. These settings
identified 123 genes by exon microarray and 117 genes by
tag-seq. However, only 30 genes were concordant, as indi-
cated in Figure 1A and listed in Table 2. The hypothesis
that the common set of genes was caused by pure chance
was clearly rejected (P-value = 1.07·10-42) [12]. A corres-
pondence curve (see Additional file 2) shows that the
common set of genes among the most significant genes
for each method is not caused by pure chance. Of the 30
concordant genes, 23 genes were highly expressed in the
pure OCI-Ly8 cell line compared to the HEK293 cell line.
The majority (19/30) of the differentially expressed genes
encoded the cluster of differentiation (CD) molecules
(CD20 (MS4A1), CD45 (PTPRC), CD52, and CD53, CD74,
CD79A and B), human leukocyte antigen molecules
(HLA-DRA), transcriptional regulators (ELF1, ETS1,
BCL6, MYB, and EBF1), B-cell-specific scaffold proteins
(BANK1), creatine kinase isoenzymes (CKB), deubiquiti-
nating enzymes (UCHL1), actin-binding proteins (LCP1),
glycosyltransferases (ST6GAL1), uncharacterised proteins
(C13orf18), and signal transduction molecules (GCET2).
The full lists of differentially expressed genes are given in
Additional files 3 and 4.
Hierarchical clustering of all samples
For both exon microarray and tag-seq, hierarchical clus-
tering of all samples based on the 123 and 117 differen-
tially expressed genes resulted in three individual
concordant clusters (Figures 1C and 1D). One cluster
contained the samples with frequencies of 0%, 0.5% and
1% malignant B-cells, a second cluster of 5%, 10%, 20%
and 30% malignant B-cells, and a cluster of the sample
containing 100% malignant B-cells. Samples with lessthan 1% malignant B-cells were not distinguishable by
hierarchical clustering from the non-B-cells of HEK293
in either exon microarray or tag-seq. Hierarchical clus-
tering of all samples based on all genes are shown in
Additional file 5.
Comparison of background level and instrument
detection limit (IDL)
Of the 123 genes differentially expressed between the
100% and 0% samples detected by exon microarray, we
identified 79 B-cell specific genes that were expressed
more highly in the 100% B-cell sample. To see whether
these 79 B-cell specific mRNA transcripts were present
in the background of the non-B-cells, the proportion of
B-cell specific mRNA transcripts with DABG was plot-
ted as a function of sample purity (Figure 1B), indicating
an increased ability to detect B-cell specific mRNA tran-
scripts as a function of sample purity. Only 4% (3 out of
79) of the B-cell specific mRNA transcripts had DABG
for the pure HEK293 cell line sample. The expression
values for the 3 transcripts with DABG were 6.21, 7.05,
and 7.02 (HIST1H3I, ST6GAL1, and ELF) and therefore
only borderline expressed. This indicates that very few
false-positive B-cell specific mRNA transcripts were de-
tectable in the pure HEK293 cell line sample. Of the 117
differentially expressed genes between 100% and 0%
samples detected by tag-seq, 61 genes were expressed
more highly in the 100% B-cell sample. All had counts
equal to zero except for 4 genes (PHYH, DNAJC2, TCF4
and ST6GAL1) that had counts of 2, 1, 3 and 1 respect-
ively in the pure HEK293 cell lines, demonstrating very
few, if any, false-positive B-cell specific mRNA tran-
scripts using the tag-seq technology.
To define where true mRNA transcripts were
present and where background levels make detection
impossible, the instrument detection limits (IDL) of
exon microarray and tag-seq were determined. By re-
gression of the mRNA expression levels of the B-cell
specific differentially expressed genes versus sample
purity under the assumption of a common back-
ground as intercept and gene-individual slopes, the
IDL was determined for both technologies (Figure 2).
For exon microarray, the resulting residual standard
deviation was estimated to be σ = 224, resulting in an
IDL of 367 when 95% confidence was used. The lin-
ear model was controlled by standardised residual
plots. For exon measurements we noticed 8 outliers
and for fitted values below the IDL a clear tendency
to measurements being below the regression line
(Additional file 6, Figure A). For measurements with
a fitted value above the IDL and an absolute value
below 3 we noticed a small tendency to increasing
variance (Additional file 6, Figure A) and deviation
from the normal distribution (Additional file 6, Figure
A93 8730
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Figure 1 Characteristics of exon microarray and tag-seq data. (A) Venn diagram illustrating numbers of differentially expressed genes
identified by exon microarray and tag-seq. An overlap of 30 differentially expressed genes between the pure OCI-Ly8 and HEK293 cell line
samples was identified between exon microarray and tag-seq. (B) Proportion of B-cell specific mRNA transcripts detected above background for
exon microarray. Hierarchical clustering of all cell populations based on differentially expressed genes between the pure samples of OCI-Ly8 and
HEK293 cell lines identified by (C) exon microarray and (D) tag-seq.
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nomial regression NB1 yielded an IDL of 18, whereas
the NB2 model yielded an IDL of 216. The NB1 and
NB2 models were controlled by quantile residual plots
(see Additional file 6, Figures C, D and E, F, respect-
ively). These plots showed reasonable fits, but the de-
viance of NB1 (2,556) was lower than the deviance of
NB2 (2,763). Therefore we chose to continue with the
NB1 model.Comparison of method detection limit (MDL)
The ability to detect genes was quantified by plotting the
MDL as a function of sample purity (Figure 2). For both
exon microarray and tag-seq, the decrease in the ability
to detect mRNA expression levels was inversely propor-
tional to sample purity. The MDL met the IDL at 100%
sample purity.
As CD74, HLA-DRA, and BCL6 are all transcripts of
importance in B-cell development, and they were among
Table 2 The 30 overlapping common expressed mRNA
transcripts between the OCI-Ly8 and HEK293 cell lines
identified by exon microarray and tag-seq
Gene Exon Tag-seq
Log2 FC Adj. P-val. MDL Log2 FC Adj. P-val. MDL
TCL1A 6.976 <0.001 4.5% 10.069 <0.001 1.9%
HLA-DRA 6.135 <0.001 12.6% 9.541 <0.001 4.0%
CD74 5.891 0.001 5.0% 10.077 <0.001 2.0%
C13orf18 6.801 <0.001 6.1% 7.401 0.008 7.9%
ARHGDIB 6.188 <0.001 9.7% 7.349 0.008 15.4%
CKB −5.573 0.002 NA −9.526 <0.001 NA
LCP1 7.108 <0.001 7.4% 6.087 0.029 27.4%
CD52 5.63 0.002 9.1% 7.209 0.010 16.9%
FHL1 −5.736 0.001 NA −6.229 0.028 NA
UCHL1 −5.212 0.006 NA −7.714 0.005 NA
APBB1IP 5.408 0.003 18.4% 6.267 0.028 25.5%
GLUL −5.323 0.004 NA −6.592 0.012 NA
CD79A 6.132 <0.001 4.8% 5.858 0.033 33.1%
GCET2 5.347 0.004 14.8% 6.129 0.029 45.2%
CD79B 4.682 0.020 7.3% 8.077 0.003 7.7%
ELF1 5.07 0.008 6.9% 6.977 0.012 12.7%
CPNE3 −5.036 0.009 NA −6.304 0.028 NA
CD53 6.122 <0.001 9.0% 5.392 0.049 47.4%
AMOT −5.189 0.006 NA −6.044 0.029 NA
ST6GAL1 5.254 0.005 5.8% 5.858 0.028 18.8%
ETS1 5.299 0.005 18.8% 5.781 0.036 26.6%
CNN3 −4.618 0.023 NA −6.066 0.029 NA
MS4A1 4.435 0.037 13.9% 5.977 0.029 37.9%
MYB 5.117 0.007 14.5% 5.392 0.049 31.8%
APP −4.419 0.039 NA −5.858 0.033 NA
PTPRC 4.799 0.015 66.4% 5.392 0.049 67.7%
BANK1 4.677 0.020 35.5% 5.426 0.049 42.6%
ACSL5 4.685 0.020 29.3% 5.392 0.049 64.8%
BCL6 4.366 0.044 21.2% 5.524 0.046 50.2%
EBF1 4.34 0.046 15.1% 5.392 0.049 77.7%
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exon microarray and tag-seq, they were selected for
comparison and verification of the MDL as a function of
sample purity (Figure 3). For exon microarray, the
mRNA expression levels of all three genes followed an
approximately linear relationship with sample purity
(Figure 3A, D, G), whereas larger fluctuations around a
linear relationship were observed for all three genes in
tag-seq (Figure 3B, E, H). Higher mRNA expression
levels were obtained for CD74 and HLA-DRA compared
to BCL6 by both exon microarray and tag-seq, support-
ing that the latter was expressed in low abundance inmalignant B-cells. Thus, samples should contain ≥5%
malignant B-cells for detection of CD74, ≥13% for detec-
tion of HLA-DRA and ≥22% for detection of BCL6 by
exon microarray. Similarly, the tag-seq ability to detect
CD74, HLA-DRA and BCL6 were at least 2%, 4%, and
51% malignant B-cells.
Validation of gene expression levels by RT-qPCR
The mRNA expression levels of CD74, HLA-DRA, and
BCL6 in all sample dilutions were validated by RT-qPCR
and plotted as a function of the sample purity, revealing
a linear relationship for all four genes (Figure 3C, F, I).
The mRNA expression levels for all three genes,
obtained by exon microarray and tag-seq as well as RT-
qPCR, were compared by calculating pair wise Spear-
man’s rank correlation coefficients. High correlations
were observed between exon microarray and RT-qPCR,
as well as tag-seq and RT-qPCR, for all three genes
(Table 3). The exon array showed better correlation to
qPCR than tag-seq did.
Discussion
The presence of tumour-infiltrating non-malignant cells
is expected to mask the detection capacity of GEPs of
malignant B-cells [3]. This study, however, suggests a
novel quantitative tool for the assessment and compari-
son of the ability of microarrays and next generation se-
quencing to detect mRNA transcripts from malignant B-
cells in a pool of non-malignant cells. Several studies
have compared exon microarrays and next generation
technologies [5,13-16]. To the best of our knowledge, no
studies have developed quantitative methods which are
able to assess the ability of exon microarray and tag-seq
to detect transcripts as a function of sample purity. We
deliberately chose to make a model system that ensured
distinct differences in cellular origin in order to observe
clearly differentially expressed genes, enabling us to
identify possible difficulties within such a model system.
A comparable number of differentially expressed genes
between the pure samples of OCI-Ly8 and HEK293 cell
lines was identified by the two technologies (Figure 1A).
Although the number of differentially expressed genes in
common between the two technologies was small across
a number of FDR settings, it was not caused by pure
chance (Additional file 2). One factor for this could be
false negatives entering due to the lack of replicates at
0% and 100% sample purity. One could also speculate
that the small number of commonly expressed genes
may be explained by different shortcomings of the plat-
forms, as probes on the exon microarray detect differen-
tially expressed genes that either contain or do not
contain the NlaIII restriction enzyme site, whereas tag-
seq only catches differentially expressed genes with the
unique CATG sequence. Therefore, some mRNA






















































Figure 2 MDL of exon microarray and tag-seq. MDL plotted as a function of sample purity by (A) exon microarray and (B) tag-seq. Full drawn
black line is the MDL estimate from the experiment. Dotted lines show MDL for a range of standard errors (exon) and dispersion parameters
(tag-seq). IDL is the instrument detection limit defined as 367 when 95% confidence was used for exon microarrays and 18 for tag-seq when the
linear mean-variance negative binomial regression was used. In the pure sample detection of signal is not possible below the IDL.
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sence of the CATG sequence, and some mRNA tran-
scripts may not be detected by exon microarrays due to
inadequate probe design for exon microarrays [15].
However, we only found 1 gene differentially expressed
by exon microarray that did not contain the NlaIII
restriction site.
A majority of the differentially expressed genes that
overlap between exon microarray and tag-seq were B-
cell specific mRNA transcripts, including CD20, CD74,
CD79A, HLA-DRA, BCL6, BANK1, C13orf18, and
TCL1A (Table 2). Most of the B-cell specific genes were
related to cell surface-expressed antigens, which is con-
sistent with the importance of interactions with external
environment in defining the characteristics of B-cells.
Uniform patterns of relatedness of samples between
exon microarray and tag-seq were observed by hierarch-
ical clustering. Even though only 30 of the differentially
expressed genes were common between exon microarray
and tag-seq, the underlying expression patterns of
mRNA transcripts were sufficient to ensure similar
results on the relatedness between samples by exon
microarray and tag-seq. Samples with ≤1% malignant B-
cells were indistinguishable from the pure non-B-cell
sample for exon microarray and tag-seq. Thus, >1% ma-
lignant B-cells should be presented in biopsies for detec-
tion of a malignant B-cell profile by exon microarray
and tag-seq, given the model system and data at hand
(Figure 1C and 1D).Based on concepts from analytical chemistry, it was
possible to show how the ability to detect single genes
(MDL) increases with sample purity (Figure 2). Both
exon microarray and tag-seq showed limitations when
studying low-abundant mRNA transcripts. A topic for
future work is to define the precision estimates of the
IDLs, MDLs and background levels as a function of dilu-
tion density and replicates. These results are important
for designing future detection ability studies. When the
precision estimates have been improved with other data
sets it will be possible to establish guidelines on how low
expression levels of mRNA transcripts are detectable in
the original sample for a given sample purity, and thus,
give advice on the detection abilities of e.g. low-abundant
transcription factors and stem cell genes.
Variance inhomogeneity was observed for the residuals
of the linear model used for the exon microarray
(Additional file 6, Figure A and B). We noticed that, for
fitted values below the IDL, there is a clear tendency to
measurements being below the regression line. This is
probably due to the measurements being below back-
ground in the region and a horizontal regression line
would be more appropriate, suggesting a piecewise regres-
sion model. This is an important observation as the usual
convolution models used in the de-convolution of signals
from measurement in array data does not take an IDL into
account. This will, however, lead to more complicated IDL
and background correction calculations and is left for
future research. Over-dispersion of gene count data from
Figure 3 Detection of B-cell specific genes by exon microarray, tag-seq, and RT-qPCR. The mRNA expression levels of CD74, HLA-DRA and
BCL6 plotted as a function of sample purity identified by exon microarray (A, D, G), tag-seq (B, E, H), and RT-qPCR (C, F, I).
Table 3 Spearman’s rank correlation coefficient of mRNA
expression levels between exon microarray, tag-seq, and
RT-qPCR
Gene Exon vs Tag-seq vs Exon vs
RT-qPCR RT-qPCR tag-seq
CD74 0.964 0.964 0.927
HLA-DRA 1.000 0.952 0.952
BCL6 0.976 0.873 0.846
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we resolved this by using the quadratic mean variance
negative binomial model, i.e. NB2, when detecting differ-
entially expressed genes, whereas we used the linear
mean-variance negative binomial model, i.e. NB1, when
analysing the IDL. NB1 is not supported in the edgeR
package but we discovered that NB1 was sufficient for the
negative binomial regression by residual plots (Additional
file 6, Figures C & D, and E & F) and comparison of
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the most appropriate dispersion model estimates for NGS
data was outside the scope of the present paper, but it is
an important topic for future research.
The ability to detect single genes by exon microarray
and tag-seq was exemplified by analysing the mRNA ex-
pression levels as a function of sample purity for three dif-
ferent B-cell mRNA transcripts. The mRNA expression
levels of CD74, HLA-DRA, and BCL6 followed a linear re-
lationship as a function of sample purity for exon micro-
array, whereas larger fluctuations were observed for tag-
seq (Figure 3). Feng et al. demonstrated an increased coef-
ficient of variation when detecting low-abundant mRNA
transcripts by tag-seq [15]. With increased sequencing
depth, detection of low-abundant mRNA transcript will
probably become more accurate [14]. Feng et al. described
the relationship between total sequence volume and infor-
mation of mRNA expression levels as a sigmoid function.
This means the deeper the sequencing, the greater the in-
formation [15]. The present work demonstrates that the
difference in the ability to detect the three genes above
depends on the sample purity and the initial abundance in
the pure B-cell sample. Tag-seq showed a tendency to
have higher ability to detect highly abundant transcripts
compared to exon microarray, supporting previous obser-
vations [5,14].
Based on the analysis of the three selected single
genes, we demonstrated that the best detection ability
corresponds to the highly abundant malignant B-cell
transcripts, and there was an actual loss in the ability to
detect low-abundant mRNA transcripts in samples with
low purity. For BCL6, as a low-abundant gene, it was
evident that a malignant B-cell frequency above 20-50%
was required for reliable transcript detection. This sup-
ports the observed proportional relationship between
the ability to detect genes and increasing sample purity.
The next obvious step for a follow-up study within this
theme is to make serial dilutions of malignant B-cells
into normal B-cells, T-cells and macrophages. Our
results show that basic requirements of detection abil-
ities can be identified and detection capabilities can be
studied in a formal framework. Other directions for fu-
ture studies include RNA-Seq on the entire poly-A frac-
tion. This may help to detect even very low-abundant
transcript, possibly helping to identify malignant B-cell
specific transcript, i.e. alternative splicing isoforms,
which are missed by tag-seq or more interestingly the
fusion transcripts, which are cancer-specific and may
dramatically help to create the conditions for establish-
ing a future model system.
Conclusions
In the present study, it was demonstrated that the devel-
oped methodological tools are valuable in assessing theability to detect genes by high-throughput platforms
capable of screening samples for tumour-specific mRNA
transcripts, but more extensive studies are needed to
give general advice on the choice of optimal technology.
An important future perspective when assessing and
comparing the detection capabilities of high-throughput
platforms is to validate the usefulness of the proposed
model system and analysis setup, by diluting pure malig-
nant lymphoma samples with normal lymph node tissue.
Methods
Laboratory work
Samples of cell lines
The cell line, OCI-Ly8, provided by Dr. Hans Messer
and Dr. Andreas Rosenwald was established at Ontario
Cancer Institute (OCI). OCI-Ly8 was established from a
patient with diffuse large B-cell lymphoma [19]. This cell
line was maintained in RPMI1640 medium (GIBCO
Invitrogen, NY, USA) including 10% foetal bovine serum
(FBS, GIBCO Invitrogen, NY, USA). Cell line HEK293
(ATCC) was generated by transformation of normal
human embryonic kidney cells with sheared adeonivrus
DNA [20]. This cell line was maintained in Eagle’s Mini-
mum Essential Medium (GIBCO Invitrogen, NY, USA)
supplemented with 10% FBS. Both cell lines were cul-
tured at 37°C in a CO2-incubator (BINDER, NY, USA)
in a humidified atmosphere supplemented with 5% CO2.
Cells were harvested in the exponential growth phase
and sorted by a BD FACSAria II Cell Sorter (BD Bio-
science, San Jose, CA, USA) to obtain eight cell popula-
tions, diluting OCI-Ly8 into HEK2932 in the cellular
concentrations 0%, 0.5%, 1%, 5%, 10%, 20%, 30%, and
100% of OCI-Ly8 and subsequently stored in Trizol Re-
agent (GIBCOBRL Invitrogen, NY, USA). Cell line iden-
tity was analysed using 0.2 ng/μl extracted RNA from
the cell lines as template in a multiplex PCR using the
AmpFISTR Identified PCR amplification kit (Applied
Biosystems, CA, USA). A fragment analysis of the ampli-
fied PCR product was performed by capillary electro-
phoresis by Eurofins Medigenomix GmbH, Applied
Genetics, Germany. The resulting FSA files were ana-
lysed using the Osiris software (http://www.ncbi.nlm.nih.
gov/projects/SNP/osiris/) given the following STR pro-
files: OCI-Ly-8: D5S818-4 (10, 13), D13S317-2 (11, 11),
D7S820-1 (11, 12), D16S539-2 (9, 11), VWA-3 (17, 19),
TH01-2 (6, 9.3), AMEL-4 (X, X), TPOX-3 (9, 11),
CSF1PO-1 (11, 12), and HEK293: D5S818-4 (8, 9),
D13S317-2 (12, 12), D7S820-1 (11, 11), D16S539-2 (9,
13), VWA-3 (16, 19), TH01-2 (7, 9.3), AMEL-4 (X, X),
TPOX-3 (11, 11), CSF1PO-1 (11, 12).
Total RNA extraction
Total RNA was extracted from the eight cell populations
using the Trizol Reagent and purified using the mirVana
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ing to the manufacturer’s protocol. The quantity of
extracted total RNA was measured on a NanoDrop ND-
1000 spectrophotometer (Thermo Scientific, Denmark),
and the quality of the total RNA was assessed using the
Agilent RNA 6000 Nano kit and Nano Series II assay in
combination with the Agilent 2100 Bioanalyzer (RIN
values >9, Agilent Technologies, Denmark). Total RNA
was stored at −80°C until use.
Affymetrix exon array
Exon microarray data were generated using 100 ng of
total RNA. Ambion WT Expression Kit (AMBION INC,
NY, USA) generated amplified and biotylated sense-
strand cDNA from the total RNA according to the man-
ufacturer’s protocol. Afterwards, single-strand cDNA
was fragmented by UDG (uracil glycosylase) and APE1
(apurinic/apyrimidinic endonuclease) and biotin-labelled
using the GeneChip Terminal Labeling and hybridisation
Kit (Affymetrix, CA, USA) according to the manufac-
turer’s protocol. 5 μg of biotin-labelled cDNA were incu-
bated with the Affymetrix GeneChip Human Exon 1.0
ST array at 45°C for 17 hours for hybridisation. Follow-
ing hybridisation, non-specific bound material was
removed by washing with the GeneChip Hybridisation,
Wash and Stain kit (Affymetrix, CA, USA) and the
GeneChip Fluidics Station 450 (Affymetrix, CA, USA).
Detection of bound material was performed by scanning
the array using the GeneChip Scanner 7G (Affymetrix,
CA, USA).
Tag preparation and sequencing
For tag preparation, 2 μg of total RNA were incubated
with magnetic Oligo-(dT) beads to capture the polyade-
nylated RNA fraction. Bound to the beads, total RNA
was reverse transcribed into double-stranded cDNA
using the SuperScript II kit (Invitrogen, NY, USA). The
double-stranded cDNA was digested with the restriction
enzyme NlaIII (New England Biolabs, MA, USA) to gen-
erate cDNA fragments from the most 3´-end CATG to
the poly(A) tail. cDNA without the NlaIII recognition
site was removed by washing. A biotinylated adaptor
containing the recognition site for the restriction en-
zyme MmeI was linked to the 5´-end of the digested
double stranded cDNA. Next, tags of 17 bp of double
stranded cDNA were released from the Oligo-(dT)25
beads by MmeI (New England Biolabs, MA, USA). Tags
were purified from a polyacrylamide gel by phenol-
chloroform extraction and bound to Streptavindin beads.
A second adapter containing an identification key of 3
bp unique for each sample was ligated to the tags. The
adaptor-ligated tags from all samples were pooled and
amplified by PCR. The PCR products were purified by
excision from a 6% polyacrylamide gel (Invitrogen, NY,USA), followed by elution, ethanol precipitation and re-
suspension (Illumina, MA, USA). The amount of adaptor-
ligated tags was quantified using the NanoDrop ND-1000
spectrophotometer (Thermo Scientific, Denmark). The
sample was stored at −20°C until sequencing. The
sequencing procedure was carried out according to the
manufacturer’s protocol. Adaptor-ligated tags from all
samples were sequenced in an individual lane of a flow
cell by the Solexa/Illumina Whole Genome Sequencer
1G analyser. Clustering and sequencing were performed
with reagents from the cluster generation kit and sequen-
cing kit (Illumina, MA, USA).
RT-qPCR
RT-qPCR data were generated using total RNA reverse
transcribed into cDNA by the SuperScript III First-
Strand Synthesis Supermix (Invitrogen, NY, USA ) and
TaqMan reagents and assays (Applied Biosystems, CA,
USA) according to the manufacturer’s protocol. 500 ng
total RNA was mixed with 50 μM Oligo(dT) primer, 50
ng/μl random hexamer primer, and Annealing buffer.
The sample was incubated in the thermal cycler at 65°C
for 5 minutes to unfold loops together with secondary
structures. Following incubation, 2x First-Strand Reac-
tion mix and SuperScript III/RNaseOUT Enzyme mix
were added to the sample, and the sample was incubated
in the thermal cycler at 25°C for 5 minutes, 50°C for 50
minutes, and then 80°C for 5 minutes. The cDNA was
used directly in RT-qPCR or stored at −20°C.
For RT-qPCR, 2x TaqMan Universal Master mix with-
out AmpErase UNG (Applied Biosystems, CA, USA)
and 20x TaqMan gene expression assay was mixed. The
cDNA product was diluted 10 times, and 4 μl of the
cDNA product was used as template. The cDNA prod-
uct was amplified using a two-step thermal profile: 95°C
for 10 minutes, followed by 50 cycles at 95°C for 15
seconds and 60°C for 1 minute.
The RT-qPCR was performed using cDNA product
and the TaqMan gene expression assays (Applied biosys-
tems, CA, USA) specific for CD74 (Hs00959496_m1),
HLA-DRA (Hs00219576_m1), and BCL6 (Hs00153368).
To correct for sample-to-sample variations in efficiencies
and errors in quantification, the TaqMan Pre-Developed
endogeneous control assay (Applied Biosystems, CA, USA),
TBP (333769F), were used for normalisation. Amplified
mRNA was detected by the Mx3000P QPCR instrument
(Stratagene, CA, USA).
Data processing and analysis
Generation of .CEL-files and gene summarization
CEL-files were generated by the Affymetrix GeneChip
Command Console Software (AGCC) and deposited at
the NCBI Gene Expression Omnibus (GEO) under ac-
cession number GSE40311. The .CEL-files were imported
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The .CEL-files were background corrected and quan-
tile normalised by the RMABackgroundCorrection and
QuantileNormalization functions from the aroma.affyme-
trix package [21]. Core probe intensities were summarised
to gene expression levels by means of the ExonRMAPlm
(, mergeGroups=TRUE) function using the customised
cdf-file for core transcripts downloaded from http://bcgc.
lbl.gov/cdfFiles/HuEx-1_0-st-v2,A20071112,EP/HuEx-
1_0-st-v2,coreR3,A20071112,EP.cdf.
Extraction, annotation and gene summarization of tag
sequences
The Illumina Pipeline software version 1.3 was used for
image analysis and base calling, omitting chastity filter-
ing, otherwise using default settings. Data were imported
into the CLC Genomics Workbench 4.5 and sequence
error corrected by the SAGEScreen method. The first 17
bp of the tag sequences were extracted from the output
file according to the second adaptor containing the iden-
tification key for each sample. The unique tags were
sorted and counted for each sample using the CLC Gen-
omics Workbench 4.5 and exported to .txt-files. These
text files were imported into Bioconductor. Due to a
large library-to-library variation in the amount of
obtained tags the set of tags in the libraries were ran-
domly sub-sampled without replacement to equal the
size of the smallest library.
Each unique tag sequence was annotated by mapping
the reads with the anchoring NlaIII restriction site to the
ENSEMBL Homo Sapiens cDNA reference transcrip-
tome (release 63) downloaded from ftp://ftp.ensemble.
org on both the coding and non-coding strands using
Bowtie version 0.12.7 [22]. The setting –v1 was used
allowing Bowtie to accept a maximum of one mismatch.
ENSEMBL identifiers were via Entrez identifiers,
mapped to gene symbols by use of the R-package Bio-
mart and the org.hs.eg.db database. The total expression
for each gene was calculated by summing all tags
mapped to the same gene. Tag-seq data were deposited
at GEO under accession number GSE40311.
Statistical analysis
All statistical analyses were done with R Version 2.13.2 (64
bit Windows version) and a number of Bioconductor
packages [23] as described below. Detailed session infor-
mation is contained in Additional file 7. P-values were false
discovery rate (FDR) corrected by the Benjamini-Hochberg
procedure and 0.05 was used as significance level.
Differentially expressed genes
Exon microarray
Since no replicates were present for the pure cell lines, it
was assumed for exon microarrays that the expressionvalue, Ygi, for the g’th gene out of G genes and the i’th
sample out of two samples is N(μgi, σ
2) - distributed.
Then, under the null hypothesis of no difference in gene
expression of gene g between sample 1 and 2, Yg1 − Yg2,









this means that P-values of the z-scores zg = (Yg1 − Yg2)/s
can be used to test the hypothesis of no difference in
gene expression levels. The P-values of the z-scores can
be FDR corrected by the Benjamini-Hochberg procedure
as implemented in the Bioconductor package fdrtool.
Tag-seq
The Bioconductor package edgeR is designed for dif-
ferential expression analysis of count data and is an
implementation of the methods developed by Robinson
and Smyth [24]. As recommended, we only keep tags
that are sufficiently expressed in at least one of the
samples by filtering tags where the count is not above
15 in any of the samples. The edgeR package models
the counts, Ygi, of a gene g in sample i as a quadratic
mean-variance negative binomial distributed random
variable
Ygi ∼ NB2 Mipgj;ϕg
 
where Mi is the library size, pgi is the relative abun-
dance of gene g, and φg is the dispersion parameter.
When the negative binominal distribution was fitted,
a common dispersion for all tags was estimated using
the Cox-Reid profile-adjusted likelihood method. FDR
corrected P-values for differentially expressed genes
were determined using an exact test.
Detection above background
In order to determine genes detected above back-
ground, the DABG algorithm of Affymetrix Power
Tools (APT) [25] version 1.14.3.1 with the instruction
“apt-probeset-summarize –a dabg” was used to find
P-values for the hypothesis that each exon belongs to
the background. The .PGF and .CLF files were used
for the exon array, and for the background correction,
the antigenomic background probes were used. Sum-
marising to gene level was performed as follows [26]:
For each gene in each sample, the number of present
exons was counted – presence is assumed whenever
the P-value was below 0.005. If half or more than half
of the exons were present, the gene was assumed to
be present in that sample, or otherwise it was absent.
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A hierarchical cluster analysis was performed on the
differentially expressed genes. The hierarchical cluster
analysis was based on the R-function hclust using
complete linkage as the agglomeration method and
Eucledian distance as dissimilarity measure.
Instrumental detection limit and method detection limit
The instrumental detection limit (IDL) is defined as the
analyte concentration required to produce a signal that
is distinguishable from the blank level with a particular
statistical confidence [27]. Formally, the blank level is
assumed equal to b, the random variable Y(t) denote a
measurement of the analyte at concentration t ≥ 0 and
the statistical confidence is chosen to be 95%. Then, the
IDL is defined as
IDL ¼ min t≥0 : P y tð Þ > bð Þ≥0:95f g:
Exon microarray measurement model
For exon microarray, the concentration, t, should be
understood as the light intensity arising from a particular
mRNA transcript hybridised to the array. It is normally
assumed that this light-intensity is directly proportional to
the number of mRNA transcripts in the sample. The coef-
ficient of proportionality depends on e.g. the array type
and reaction efficiency. Hence, for exon microarrays, the
following measurement model is assumed
Y tð Þ ¼ t þ bþ ε tð Þ;
where ε(t) is assumed to be N(0, σ2) -distributed. In this
case
IDL ¼ min t≥0 : P t þ bþ ε tð Þ > bð Þ≥0:95f g
¼ min t≥0 : P ε tð Þ > Tð Þ≥0:95f g
¼ 1:64σ:
The method detection limit (MDL) will in practice de-
pend on the sample purity. If p, 0 ≤ p ≤ 1, is denoted as
the ratio between the tumour and normal samples, the
following measurement model is assumed
Y tð Þ ¼ pt þ bþ ε tð Þ:
Then, it is straightforward to calculate the MDL as a
function of the sample purity p in the following way
MDL pð Þ ¼ min t≥0 : P pt þ bþ ε tð Þ > bð Þ≥0:95f g











:This shows that the MDL is inversely proportional to
the sample purity. The IDL can be estimated by dilution
curves as follows: Let the gene expression be measured
at the following dilutions of the k’th transcript, tkxi
where 0 = x1 ≤ ⋯ ≤ xn = 1, then, for exon microarray,
this means that b, tk and σ can be estimated by the linear
regression model
ykt ¼ tkxt þ bþ εkt
where εki ~ N(0, σ
2). This is done by means of least
squares regression as implemented in the lm-function in
R. Model control is performed by plotting the standar-
dised residuals vs. the fitted values and normal probabil-
ity plots of the standardised residuals. Standardised
residuals above 3 are considered outliers and plotted on
a log-transformed scale.
Tag-seq measurement model
For tag-seq, concentration, t, should be understood as
the expected count number of a particular mRNA tran-
script. It is normally assumed that the expected count
number is directly proportional to the number of mRNA
transcripts in the sample. The coefficient of proportion-
ality depends on e.g. the sequencing method and cover-
age depth. Hence, for tag-seq, it is assumed that b = 0.
In the following we calculate the IDL for two models in-
corporating over-dispersion.
First consider the linear mean-variance negative binomial
distribution NB1 where Y(t) is NB1(μ, θ) -distributed, i.e.
NB1(μ, θ) is the linear mean-variance negative binomial
distribution, with dispersion parameter θ, mean μ and
variance μ + θμ. The pmf of this distribution is [28]









1þθð Þ − μθ :In this case
IDL ¼ min t≥0 : P Y tð Þ > 0ð Þ≥0:95f g
¼ min t≥0 : 1 P Y tð Þ ¼ 0ð Þ≥0:95f g







¼ t≥0 : t≥ θlog20




log20 1þ θð Þ
:
This implies that in order to reliably observe an
mRNA transcript, the expected count for the mRNA
transcript should be more than θ/log20(1 + θ) counts in
the specific experimental setup.
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nomial distribution NB2 where Y(t) is NB2(t, θ) -distribu-
ted, i.e. NB2(μ, θ) is the quadratic mean-variance negative
binomial distribution, with dispersion parameter θ, mean
μ and variance μ + θμ2. The pmf of this distribution is









1þμθð Þ − 1θ :In this case
IDL ¼ min t≥0 : P Y tð Þ > 0ð Þ≥0:95f g
¼ min t≥0 : 1 P Y tð Þ ¼ 0ð Þ≥0:95f g
















This implies that in order to reliably observe an
mRNA transcript, the expected count for the mRNA
transcript should be more than (20θ − 1)/θ counts in the
specific experimental setup.
The method limit of detection (MLD) for both the
NB1 and NB2 model will in practice depend on the sam-
ple purity. If p, 0 ≤ p ≤ 1, is defined to be the ratio be-
tween the amount of tumour and normal sample, the
following measurement model is assumed
Y tð Þ ∼ NBx pt; θð Þ;where x ¼ 1; 2:
Then, it is straightforward to calculate the MDL as
function of p
MDL pð Þ ¼ IDL
p
:
This shows that the MDL is inversely proportional to
the sample purity. The IDL is estimated by dilution
curves in the following way: Let the transcript be mea-
sured at the following dilutions of the k’th transcript,
tkxi, where 0 = x1 ≤ ⋯ ≤ xn ≤ 1, then, for tag-seq, this
means that tk is estimated by a negative binomial regres-
sion model with log-link
ykt ∼ NBx μkt ; θ
 
where ak = log tk and x = 1, 2. This is done by means of
maximum likelihood estimation of the parameters as
implemented with the gamlss-function in R [29]. Model
control can be performed by plotting the quantile resi-
duals vs. the fitted values and normal probability plots of
the quantile residuals. Models can be compared by the
deviance.Cross platform reproducibility analysis
We assessed the cross platform reproducibility by means
of correspondence curves [30]. A correspondence curve is
constructed by ranking the genes according to their sig-
nificance for each of the two experiments. Then the num-
ber of genes in common is plotted against the number of
significant genes. Under perfect concordance this plot will
behave like y = x and under random sampling it will be-
have like y=x2. The acceptance region at a given level of
significance for the hypothesis of random sampling can be
constructed by the hypergeometric distribution [12].
RT-qPCR
For determination of mRNA expression levels by RT-
qPCR measurements were performed in triplicates, and
the average cycle thresholds (Cq) were used to deter-
mine fold-change. The mRNA expression levels were
determined by the ΔΔCq method [24] using TBP as
reference gene and the pure OCI-Ly8 cell line as refer-
ence sample. No reverse transcription and no template
control samples were used as controls.
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